Better infrastructure: Industry-academia partnerships - A marriage of convenience?

Critical Care Medicine

Volumn 37, Issue SUPPL. 1, 2009, Pages

  Abraham, Edward ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Academia; Acute lung injury; Clinical trials; Conflict of interest; Coordinating center; Critical illness; Data safety monitoring board; Ethics; Industry; Sepsis

Indexed keywords

CLINICAL STUDY; CLINICAL TRIAL; CONFLICT OF INTEREST; CRITICAL ILLNESS; DATA ANALYSIS; DRUG EFFECT; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; FUNDING; GOVERNMENT REGULATION; HEALTH CARE INDUSTRY; HUMAN; MEDICAL EDUCATION; METHODOLOGY; MONITORING; PATIENT; PATIENT PARTICIPATION; PATIENT SAFETY; PRIORITY JOURNAL; PUBLICATION; REVIEW; RISK ASSESSMENT; ARTICLE; COOPERATION; INDUSTRY; MEDICAL SCHOOL; PATIENT SELECTION; PROFESSIONAL STANDARD; STATISTICAL ANALYSIS;

CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS DATA MONITORING COMMITTEES; CONFLICT OF INTEREST; COOPERATIVE BEHAVIOR; DATA INTERPRETATION, STATISTICAL; FACULTY, MEDICAL; HUMANS; INDUSTRY; PATIENT SELECTION;

EID: 58849104038     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181920725     Document Type: Article

References (47)

1. Johnston BC, Vohra S: Investigator-initiated trials are more impartial. Nature 2006; 443: 144
2. Molenberghs G, Imrey P, Drake C: Conflicts of interest and independent data analysis in industry-funded studies. JAMA 2005; 294: 2575-2576; author reply 2576-2577
3. Halperin SA, Scheifele D, Duval B, et al: Conforming to ICMJE principles. CMAJ 2005; 173:1358-1359
4. Wiedermann CJ: Bioethics, the surviving sepsis campaign, and the industry. Wien Klin Wochenschr 2005; 117:442-444
5. Sleight P: Where are clinical trials going? Society and clinical trials. J Intern Med 2004; 255:151-158
6. Bhandari M, Busse JW, Jackowski D, et al: Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ 2004; 170:477-480
7. Amsden GW: Industry sponsorship in research and publishing: Who is really to blame for perceived bias? Ann Pharmacother 2004; 38:714-716
8. Ferris LE, Naylor CD: Physician remuneration in industry-sponsored clinical trials: The case for standardized clinical trial budgets. CMAJ 2004; 171:883-886
9. Baird P: Getting it right: Industry sponsorship and medical research. CMAJ 2003; 168: 1267-1269
10. Evans GR, Packham DE: Ethical issues at the university-industry interface: A way forward? Sci Eng Ethics 2003; 9:3-16
11. Morin K, Rakatansky H, Riddick FA Jr, et al: Managing conflicts of interest in the conduct of clinical trials. JAMA 2002; 287:78-84
12. Landow L: Sponsorship, authorship, and accountability. N Engl J Med 2002; 346: 290-292
13. Gibson E, Baylis F, Lewis S: Dances with the pharmaceutical industry. CMAJ 2002; 166: 448-450
14. Miller FG, Shorr AF: Ethical assessment of industry-sponsored clinical trials: A case analysis. Chest 2002; 121:1337-1342
15. Polk HC Jr, Bowden TA Jr, Rikkers LF, et al: Scientific data from clinical trials: Investigators responsibilities and rights. J Trauma 2002; 52:1017-1018
16. Martin JB, Reynolds TP: Academic-industrial relationships: Opportunities and pitfalls. Sci Eng Ethics 2002; 8:443-454
17. Hirsch LJ: Conflicts of interest in drug development: The practices of Merck & Co., Inc. Sci Eng Ethics 2002; 8:429-442
18. Schieppati A, Perico N, Remuzzi G: Conflict of interest as seen from a researcher's perspective. Sci Eng Ethics 2002; 8:337-342
19. Davidoff F, DeAngelis CD, Drazen JM, et al: Sponsorship, authorship, and accountability. N Engl J Med 2001; 345:825- 826; discussion 826-827
20. Rutherford RB, Johnston KW: Potential problems with industry-supported clinical research. J Vasc Surg 2000; 31:1066-1076
21. Bodenheimer T: Uneasy alliance-Clinical investigators and the pharmaceutical industry. N Engl J Med 2000; 342:1539-1544
22. Laine C, Horton R, DeAngelis CD, et al: Clinical trial registration-Looking back and moving ahead. N Engl J Med 2007; 356: 2734-2736
23. Lott JP: Trial registration. N Engl J Med 2007; 356:1581; author reply 1581
24. Bonati M, Pandolfini C: Trial registration, the ICMJE statement, and paediatric journals. Arch Dis Child 2006; 91:93
25. Haug C, Gotzsche PC, Schroeder TV: Registries and registration of clinical trials. N Engl J Med 2005; 353:2811-2812
26. Zarin DA, Tse T, Ide NC: Trial registration at ClinicalTrials.gov between May and October 2005. N Engl J Med 2005; 353:2779-2787
27. Steinbrook R: Registration of clinical trials-Voluntary or mandatory? N Engl J Med 2004; 351:1820-1822
28. De Angelis C, Drazen JM, Frizelle FA, et al: Clinical trial registration: A statement from the International Committee of Medical Journal Editors. N Engl J Med 2004; 351: 1250-1251
29. Steinbrook R: Public registration of clinical trials. N Engl J Med 2004; 351:315-317
30. Campbell EG, Weissman JS, Ehringhaus S, et al: Institutional academic industry relationships. JAMA 2007; 298:1779-1786
31. Opal S, Laterre PF, Abraham E, et al: Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med 2004; 32: 332-341
32. Abraham E, Laterre PF, Garg R, et al: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353:1332-1341
33. Bernard GR, Margolis BD, Shanies HM, et al: Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): A single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest 2004; 125: 2206-2216
34. Jiang K, Higgins SB, Swindell BB, et al: CommLog: A communication log system for clinical trials. IEEE Trans Inf Technol Biomed 2003; 7:378-383
35. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
36. DAMOCLES Study Group, NHS Health Technology Assessment Programme: A proposed charter for clinical trial data monitoring committees: Helping them to do their job well. Lancet 2005; 365:711-722
37. Shepherd R, Macer JL, Grady D: Planning for closeout-From Day One. Contemp Clin Trials 2008; 29:136-139
38. Champion HR, Fingerhut A, Escobar MA, et al: The role of data and safety monitoring in acute trauma resuscitation research. J Am Coll Surg 2007; 204:73-83
39. Slutsky AS, Lavery JV: Data safety and monitoring boards. N Engl J Med 2004; 350: 1143-1147
40. Grant AM, Altman DG, Babiker AB, et al: Issues in data monitoring and interim analysis of trials. Health Technol Assess 2005; 9:1-238, iii-iv.
41. Clemens F, Elbourne D, Darbyshire J, et al: Data monitoring in randomized controlled trials: Surveys of recent practice and policies. Clin Trials 2005; 2:22-33
42. Sydes MR, Altman DG, Babiker AB, et al: Reported use of data monitoring committees in the main published reports of randomized controlled trials: A cross-sectional study. Clin Trials 2004; 1:48-59
43. Lee SM, Wise R, Sternberg AL, et al: Methodologic issues in terminating enrollment of a subgroup of patients in a multicenter randomized trial. Clin Trials 2004; 1:326-338
44. Abraham E, Reinhart K, Opal S, et al: Effi-cacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 2003; 290:238-247
45. Hargreaves S: Ghost authorship of industry funded drug trials is common, say researchers. BMJ 2007; 334:223
46. Gotzsche PC, Hrobjartsson A, Johansen HK, et al: Ghost authorship in industry-initiated randomised trials. PLoS Med 2007; 4:e19
47. Moore N: Transparency and trust: Clear definition of ghost writing would be helpful. BMJ 2004; 329:1345-1346